- Home
- LGCL vs RFL Comparison
LGCL vs RFL Comparison
Compare LGCL & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGCL
- RFL
- Stock Information
- Founded
- LGCL 2009
- RFL 2017
- Country
- LGCL China
- RFL United States
- Employees
- LGCL N/A
- RFL N/A
- Industry
- LGCL
- RFL Real Estate
- Sector
- LGCL
- RFL Finance
- Exchange
- LGCL NYSE
- RFL Nasdaq
- Market Cap
- LGCL 48.3M
- RFL 51.1M
- IPO Year
- LGCL 2024
- RFL N/A
- Fundamental
- Price
- LGCL $0.52
- RFL $1.99
- Analyst Decision
- LGCL
- RFL
- Analyst Count
- LGCL 0
- RFL 0
- Target Price
- LGCL N/A
- RFL N/A
- AVG Volume (30 Days)
- LGCL 2.5M
- RFL 29.7K
- Earning Date
- LGCL 11-22-2024
- RFL 03-12-2025
- Dividend Yield
- LGCL N/A
- RFL N/A
- EPS Growth
- LGCL 11.49
- RFL N/A
- EPS
- LGCL 0.14
- RFL N/A
- Revenue
- LGCL $173,306,912.00
- RFL $697,000.00
- Revenue This Year
- LGCL N/A
- RFL N/A
- Revenue Next Year
- LGCL N/A
- RFL N/A
- P/E Ratio
- LGCL $3.76
- RFL N/A
- Revenue Growth
- LGCL N/A
- RFL 151.62
- 52 Week Low
- LGCL $0.47
- RFL $1.29
- 52 Week High
- LGCL $5.00
- RFL $2.50
- Technical
- Relative Strength Index (RSI)
- LGCL N/A
- RFL 47.42
- Support Level
- LGCL N/A
- RFL $1.99
- Resistance Level
- LGCL N/A
- RFL $2.12
- Average True Range (ATR)
- LGCL 0.00
- RFL 0.09
- MACD
- LGCL 0.00
- RFL -0.01
- Stochastic Oscillator
- LGCL 0.00
- RFL 50.00
About LGCL LUCAS GC LIMITED
Lucas GC Ltd is a technology-driven online agent-centric human capital management service provider targeting professionals based on PaaS in China.
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc is a holding company with interests in clinical and early-stage pharmaceutical companies. Its primary focus is to expand its investment portfolio through opportunistic investments including therapeutics, which address high unmet medical needs. Through the companies it has invested in, the company is focused on; developing Trappsol Cyclo its clinical program, developing instruments to advance minimally invasive surgeries, preclinical cancer metabolism research operations, and developing pharmaceutical-grade technology Unlokt for third-party cannabis manufacturers. It also holds and manages commercial real estate assets in Jerusalem, Israel. The company's reportable segments are; Infusion Technology, which derives maximum revenue, Healthcare, and Real Estate.